Biochemical Engineering
CureVac banks $213M IPO to push COVID-19 vaccine
14th August 2020
On the heels of a $640 million private round, Germany’s CureVac has netted $213 million in its Nasdaq debut. The bulk of the proceeds will bankroll its mRNA vaccine for COVID-19, with the rest going to manufacturing, platform development and other programs. Source: Fierce Biotech 14/8/2020
Back to group news